Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 144
- 试验地点
- 2
- 主要终点
- Sleep variability
研究概览
简要总结
Up to 40% of adults with type 1 diabetes have insufficient sleep which is associated with negative health consequences including poor blood glucose control and greater diabetes complications. In this study, a sleep intervention (Sleep-Opt) that uses wearable sleep tracking technology, telephone coaching and informational content designed to improve sleep and glycemic control in working-age adults with type 1 diabetes. Sleep-Opt could lead to reduced development of diabetes complications and improve quality of life for adults with type 1 diabetes.
详细描述
Despite improvements in treatment regimens and technology, less than 20% of adults with type 1 diabetes (T1D) achieve glycemic targets. Sleep is increasingly recognized as a potentially modifiable target for improving glycemic control. Diabetes distress, poor self-management behaviors, and reduced quality of life (QoL) have also been linked to sleep variability and insufficient sleep duration. The American Diabetes Association Standards of Medical Care in Diabetes incorporated sleep as an important component of the medical evaluation in persons with diabetes. However, no specific recommendation was given as to how to improve sleep. A significant gap of knowledge exists regarding the effects of sleep optimization on glycemic control in T1D. The purpose of this study is to determine the efficacy of a T1D-specific sleep optimization intervention (Sleep-Opt) on the primary outcomes of sleep variability, sleep duration and glycemic control (A1C); other glycemic parameters (glycemic variability, time in range), diabetes distress, self-management behavior, QoL, and other patient reported outcomes in working-age adults with T1D and habitual increased sleep variability or short sleep duration. To achieve these aims, a randomized controlled trial is planned in 120 working age adults (18 to 65 years) with T1D. Participants will be screened for habitual sleep variability (> 1 hour/week) or insufficient sleep duration (< 6.5 hours per night). Eligible subjects will be randomized to the Sleep-Opt group or healthy living attention control group for twelve weeks. A one-week run-in period is planned, with baseline measures of sleep by actigraphy (sleep variability and duration), glycemia (A1C and related glycemic measures: glycemic variability and time in range using continuous glucose monitoring), and other secondary outcomes: diabetes distress, self-management behaviors, quality of life and additional patient-reported outcomes. Sleep-Opt is a technology-assisted behavioral sleep intervention that this study team developed that leverages the rapidly increasing public interest in sleep tracking by consumers (+500% in 3 years). The behavioral intervention employs four elements: a wearable sleep tracker, didactic content, an interactive smartphone application, and brief telephone counseling. The attention control group will participate in a healthy living information program. At midpoint (Week 6) completion (Week 12) and post-program (Week 24), baseline measures will be repeated to determine differences between the two groups and sustainability of the intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults aged 18-65 years
- •clinical diagnosis of type 1 diabetes minimum of one year
- •reported habitual sleep variability (1 hour/week or more) or sleep duration less than 6.5 hrs/night during work- or weekdays (confirmed with actigraphy sleep watch)
- •a desire to improve sleep
- •own a smartphone
排除标准
- •insomnia symptoms
- •at high risk for obstructive sleep apnea
- •severe hypoglycemia episode in the past 6 months (e.g. loss of consciousness)
- •A1C greater than 10%
- •rotating shift or night shift work
- •use of sleep medications/aids
- •renal impairment (estimated glomerular filtration rate < 45 ml/min)
- •significant current medical morbidities (such as heart failure, cirrhosis, chronic obstructive pulmonary disease requiring oxygen, active treatment for cancer, depression, history of stroke with neurological deficits
- •breast feeding, pregnant, or planning pregnancy
结局指标
主要结局
Sleep variability
时间窗: Change from week 0, 6, 12, 24
Standard deviation total sleep time for one week
Sleep duration
时间窗: Change from weeks 0. 6, 12, 24
total sleep time
Glycemic control
时间窗: Change from week 0. 6, 12, 24
HbA1c blood test
Sleep Variability Week 6
时间窗: Week 6
Standard deviation total sleep time for one week
Sleep Variability Week 12
时间窗: Week 12
Standard deviation total sleep time for one week
Sleep Variability Week 24
时间窗: Week 24
Standard deviation total sleep time for one week
Sleep Duration Week 6
时间窗: Weeks 6
total sleep time minutes
Sleep Duration Week 12
时间窗: Week 12
total sleep time in minutes
Sleep Duration Week 24
时间窗: Week 24
total sleep time in minutes
HbA1C Week 6
时间窗: Week 6
Hemoglobin A1C week 6, %
HbA1C Week 12
时间窗: Week 12
HbA1c blood test
HbA1C Week 24
时间窗: Week 24
HbA1c blood test
次要结局
- Self-management behavior(Change from week. 6, 12, 24)
- Fatigue(Change from week 0. 6, 12, 24)
- Mood(Change from week 0. 6, 12, 24)
- Diabetes distress(Change from week 0. 6, 12, 24)
- Diabetes Distress Week 6(Week 6)
- Diabetes Distress Week 12(Week 12)
- Glucose Time-in-range Week 12(Week 12)
- Diabetes Distress Week 24(Week 24)
- Self-management Behavior Week 6(Week 6)
- Self Management Behavior Week 12(Week 12)
- Self Management Behavior Week 24(Week 24)
- Quality of Life Week 6(Week 6)
- Quality of Life Week 12(Week 12)
- Quality of Life Week 24(Week 24)
- Fatigue Week 6(Week 6)
- Fatigue Week 12(Week 12)
- Fatigue Week 24(Week 24)
- Mood Week 6(Week 6)
- Mood Week 12(Week 12)
- Mood Week 24(Week 24)
- Subjective Sleep Quality Week 6(Week 6)
- Subjective Sleep Quality Week 12(Week 12)
- Subjective Sleep Quality Week 24(Week 24)
- Glycemic Variability Week 6(Week 6)
- Glycemic Variability Week 12(Week 12)
- Glycemic Variability Week 24(Week 24)
- Glucose Time-in-range Week 6(Week 6)
- Glucose Time-in-range Week 24(Week 24)
研究者
Pamela Martyn-Nemeth
Professor
University of Illinois at Chicago
